Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JNZLF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
PCA-062
|
|||||
| Synonyms |
NOV-10; PCA 062; PCA-062; PCA-pCAD; PCA06 2, NOV-10; PCA062
Click to Show/Hide
|
|||||
| Organization |
MorphoSys AG; Novartis AG
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
3.8
|
|||||
| Structure |
|
|||||
| Antibody Name |
CQY684
|
Antibody Info | ||||
| Antigen Name |
Cadherin-3 (CDH3)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
emtansine
|
|||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Disease Control Rate (DCR) |
22.60% (31 patients with other tumors)
33.30% (HNSCC) 22.20% (esophageal cancer) |
|||
| Patients Enrolled |
Advanced solid tumors expressing P-cadherin, TNBC, head and neck squamous cell carcinoma (HNSCC), esophageal cancer, cervical cancer, and non-small cell lung cancer (NSCLC).
|
||||
| Administration Dosage |
At 10 different dose levels of PCA062, ranging from 0.40 to 5.00 mg/kg every 2 weeks administered as a 1-hour intravenous infusion.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02375958 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 multi-center, open-label dose escalation and expansion study of PCA062 administered intravenously in adult patients with p-CAD positive tumors. | ||||
| Primary Endpoint |
The MTD was PCA062 3.60 mg/kg every 2 weeks.No patient achieved a complete response. Only 1 patient with stage IV metastatic HNSCC treated at 0.90 mg/kg achieved a confirmed partial response (PR) as best overall response (BOR). The disease control rate (DCR) for the 31 patients with other tumors was 22.60% (95% CI, 9.60-41.10). In patients with HNSCC (n = 6), DCR was 33.30% (95% CI, 4.30-77.70), and in patients with esophageal cancer (n = 9), DCR was 22.20% (95% CI, 2.80-60.00).
Click to Show/Hide
|
||||
References